ENB Therapeutics

Name

ENB Therapeutics

Legal name

ENB Therapeutics, Inc.

Website

https://enbpharma.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Immuno-oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

Keywords

• Cancer immunotherapy drugs
• ETBR inhibitor therapy
• Clinical-stage biopharmaceuticals
• Immuno-oncology pipeline
• Combination cancer therapy

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: As a clinical-stage biopharmaceutical company, ENB Therapeutics generates revenue through successful development and potential commercialization of its ETBR inhibitor pipeline candidates, including ENB-003 and future pipeline products. Revenue would come from product sales following regulatory approval, with potential for partnership agreements, licensing deals, and milestone payments from pharmaceutical collaborators.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

ENB Therapeutics develops a pipeline of small molecule endothelin B receptor (ETBR) inhibitors designed to overcome immunotherapy resistance in solid tumors. The lead candidate ENB-003 is a first-in-class selective ETBR inhibitor being investigated in Phase 1/2 trials in combination with pembrolizumab for advanced solid tumors including platinum-refractory ovarian, pancreatic, and melanoma cancers. Second-generation candidates (ENB-004 through ENB-007) are in preclinical and discovery stages, including an oral bioavailability candidate and a CNS-targeted compound.

Product overview

ENB Therapeutics is developing a pipeline of ETBR (endothelin B receptor) inhibitors as a novel class of cancer therapeutics. The lead product ENB-003 is a first-in-class small molecule currently in Phase 1/2 clinical trials in combination with pembrolizumab. Additional pipeline candidates include second-generation oral (ENB-004) and discovery-stage compounds (ENB-005, ENB-006, ENB-007) with varying profiles including CNS-targeted delivery.

Differentiator

Problem solved

Functional benefit

Products and services

• ENB-003 First-in-class selective small molecule endothelin B receptor (ETBR) inhibitor drug candidate being investigated in Phase 1/2 clinical trials in combination with pembrolizumab for the treatment of immunotherapy-resistant solid tumors including platinum-refractory/resistant ovarian cancer, melanoma, pancreatic cancer, HNSCC, and TNBC. Blocks ETBR to restore T-cell trafficking to tumors and promotes intratumoral tertiary lymphoid organ (TLO) formation.
• ENB-004 Second-generation endothelin B receptor inhibitor with oral bioavailability, currently in preclinical development as part of ENB's pipeline expansion beyond the lead IV-formulated candidate.
• ENB-005 Second-generation endothelin B receptor inhibitor in discovery stage, characterized as highly potent and selective, part of ENB's next-generation pipeline.
• ENB-006 Second-generation endothelin B receptor inhibitor in discovery stage, characterized as highly potent and selective, part of ENB's next-generation pipeline.
• ENB-007 CNS-targeted second-generation endothelin B receptor inhibitor in ongoing discovery efforts, intended for central nervous system indications including potential glioblastoma applications.

Quantifiable outcome

• 40% ORR and 80% DCR in metastatic MSS PROC patients (N=5), with 2 partial responses showing 95% and 33% tumor reduction
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Coherus BioSciencescoreStrategic or Co-development Partner · 8 May 2024Clinical collaboration with Cancer Research Institute (CRI) for IPROC platform study evaluating LOQTORZI (toripalimab-tpzi) with ENB-003 for treatment of platinum-resistant high-grade serous ovarian cancer. Coherus supplies toripalimab-tpzi under clinical supply agreement with CRI.
• Cancer Research Institute (CRI)coreStrategic or Co-development Partner · 8 May 2024IPROC (Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer) platform trial - adaptive design study evaluating multiple immunotherapy combinations. CRI leads the study with scientific experts from its global network including principal investigator Dr. John Stagg from University of Montreal/CHUM.
• Merck (MSD outside US)coreStrategic or Co-development Partner · 4 February 2019Clinical collaboration agreement with Merck to evaluate ENB-003 in combination with KEYTRUDA (pembrolizumab) in a Phase 1/2 trial for patients with advanced solid tumors including anti-PD-1 resistant melanoma, platinum-resistant ovarian, and pancreatic cancer. ENB Therapeutics sponsors the study while Merck provides pembrolizumab.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Peers

• Merck & Co. (Keytruda):

Direct peers

• Compugen: Clinical-stage immuno-oncology company developing novel therapeutics targeting the tumor microenvironment to address resistance to checkpoint inhibitors; comparable approach of identifying novel targets in the immune resistance pathway similar to ENB's ETBR focus.
• Werewolf Therapeutics: Clinical-stage company developing INDUKINE molecules designed to be selectively activated in the tumor microenvironment to overcome resistance to immunotherapy; comparable in focusing on TME-targeted approaches for IO resistance similar to ENB's mechanism.
• Arcus Biosciences: Clinical-stage immuno-oncology company developing small molecule agents (e.g., adenosine pathway inhibitors, TIGIT antibodies) to overcome immunotherapy resistance; directly comparable in modality (small molecules and combos) and indication focus to ENB Therapeutics.
• Trishula Therapeutics: Clinical-stage immuno-oncology company developing antibodies targeting CD39 in the adenosine pathway to overcome immunotherapy resistance; comparable early-stage IO resistance play with combination checkpoint inhibitor development focus.
• Infinity Pharmaceuticals: Clinical-stage oncology company developing small molecule immuno-oncology agents (e.g., PI3K-gamma/delta inhibitors) targeting the tumor microenvironment; comparable as a small-molecule IO company focused on resistance mechanisms and combination therapy.

Emerging players

• Surface Oncology: Clinical-stage immuno-oncology company developing antibody-based therapies targeting the tumor microenvironment to address resistance to existing immunotherapies; comparable IO resistance focus and clinical-stage partnership-driven model.
• Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating antibody-drug conjugates (ISACs) to convert cold tumors to hot tumors; directly comparable mechanism of converting 'cold' to 'hot' tumors, though using biologics rather than small molecules.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/enb-therapeutics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENB Therapeutics